Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 15, Issue 12, Pages 807-809Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2016.254
Keywords
-
Ask authors/readers for more resources
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
